AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

James B. Bussel(Cornell University), Janet L. Nichol(Amgen (United States)), Roger M. Lyons(Hematology Oncology Associates), Reggie Kelly(Amgen (United States)), David J. Kuter(Harvard University), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), James N. George(University of Oklahoma), Israel Wiznitzer(Broward Health), Jorge J. Nieva(University of Southern California), Alan Lichtin(Cleveland Clinic), Robert McMillan(Scripps Research Institute), George T. Conklin(Austin Diagnostic Clinic), Chien-Feng Chen(Amgen (United States)), Jeffrey S. Wasser(Community Cancer Center)
New England Journal of Medicine
October 18, 2006
10.1056/nejmoa054626
Cited by 530

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772